FDA granted approval for Pfizer's updated vaccine on September 2, 2025.
4 reports, 3 independent
Updated Sep 2
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 4
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA granted approval for Pfizer's updated vaccine on September 2, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA approved Pfizer's updated vaccine.1 source
Pfizer gained FDA approval for its SBLA, enabling U.S.-wide availability starting August 28, 2025.1 source
Keep exploring
The entities involved
Related events
- The FDA has approved the XFG variant formula for U.S. use, and Pfizer is now deploying the approved vaccine doses across the United States.
- Pfizer and Valneva are partnering on a Lyme vaccine and are currently seeking necessary approval from the FDA.
- FDA and Pfizer are seeking regulatory approval for their products.
- Lawsuit filed alleging Pfizer engaged in deceptive marketing regarding vaccine efficacy rates.
- Roivant Sciences licensed a drug from Pfizer for regulatory approval.
Coverage
Newest first; wire copies grouped- Insider MonkeyPfizer Inc. (PFE)’s Updated COVID-19 Vaccine COMIRNATY LP.8.1 Gets FDA Approval, Ships Nationwide We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. Pfizer I
- Simply Wall St.A Look at Pfizer’s Valuation After FDA Approval of Next-Gen COVID Vaccine for Older Adults and High-Risk Groups If you have been watching Pfizer (PFE), the latest FDA approval is hard to ignore. On A
- Insider MonkeyPfizer (PFE) Announces FDA Approval of sBLA for Pfizer-BioNTech COVID-19 Vaccine Pfizer Inc. (NYSE:PFE) is one of the top most undervalued low volatility stocks to buy now. Pfizer Inc. (NYSE:PFE) ann
- GlobeNewswirePfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19 The 2025-2026 COVID-19 vaccine formulation